Boule Diagnostics – Nomination Committee for the 2023 Annual General Meeting

The Annual General Meeting, (”AGM”), 2022 of Boule Diagnostics AB (publ), (”Boule”), decided that a Nomination Committee based on the ownership structure as per September 30, 2022, will be appointed to propose for the AGM of 2023 the following items:

1. chairman of the AGM,
2. members of the board of directors,
3. chairman of the board,
4. remuneration to the members of the board and remuneration for additional committee work for each board member,
5. auditor in charge,
6. remuneration to the auditor,
7. changes to the principles and instructions for the Nomination Committee, to the extent deemed necessary, and
8. other items that fall on the Nomination Committee in accordance with The Swedish Corporate Governance Code.

Boule’s largest shareholders at the date above were AB Grenspecialisten, Svolder AB and Thomas Eklund, who combined represent just over 35 percent of share capital and votes. Said shareholders have in turn nominated Ulf Hedlundh (Svolder AB), Erik Ivarsson (AB Grenspecialisten) and Thomas Eklund. The Nomination Committee has subsequently constituted and elected Ulf Hedlundh as chairman of the committee and Yvonne Mårtensson, the chairman of the board, as an adjunct member of the Nomination Committee.

Shareholders who wish to contact the Nomination Committee are welcome to contact the committee’s chairman, Ulf Hedlundh, by email at ulf.hedlundh@svolder.se or by phone on +46 8-440 37 70. To ensure that proposals will have enough time to be evaluated properly, proposals should be submitted by February 1, 2023, at the latest.

For further information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone. +46 (0)70-689 05 90
Annette Colin, CFO, Boule Diagnostics AB, phone +46 (0)70-319 06 76

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on October 28, 2022.

Boule Diagnostics – Nomination Committee 2023